PK, Tolerability and Safety of the Co-administration of Sancuso® (Transdermal Granisetron) and IV Granisetron

Inclusion Criteria: * Healthy male or female Caucasian subjects * Aged between 18 and 70 years, inclusive, at screening * BMI between 20.0 and 29.9 kg/m², inclusive. * Must demonstrate understanding of the purposes and risks of the study * Must agree to follow the restrictions and schedule of study procedures Exclusion Criteria: * Current or previous disease, disorder, allergy or condition that could affect study conduct or laboratory assessments, or that presents undue risk from study medication or procedures. * Physical examination or screening investigation result that indicates subject is unfit for the study. * Scarring on upper arms. * Positive virology, urine drugs of abuse or pregnancy test result (females of childbearing potential only). * Recent use of prescribed or over the counter medication. * Participation in any clinical study or loss of ≥ 400 mL of blood (e.g. been a blood donor) within the previous 60 days. * Average weekly alcohol consumption of greater than 21 units (males) or 14 units (females), or habitually smokes ≥ 5 cigarettes or equivalent tobacco per day within the 6 months before the first study drug administration. * Lactating female subjects and female subjects of childbearing potential who are not willing to use an acceptable form of contraception during and for 90 days after the study.